Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort

被引：19

作者：

Bours, S. ^{[1
]}

de Vries, F. ^{[2
,3
,4
,5
,13
]}

van den Bergh, J. P. W. ^{[7
,8
,9
]}

Lalmohamed, A. ^{[2
,10
]}

van Staa, T. P. ^{[2
,6
]}

Leufkens, H. G. M. ^{[2
]}

Geusens, P. P. P. ^{[1
,9
]}

Drent, M. ^{[11
,12
]}

Harvey, N. C. ^{[3
]}

机构：

[1] Maastricht Univ, Subdiv Rheumatol, Dept Internal Med, Med Ctr, NL-6200 MD Maastricht, Netherlands

[2] Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands

[3] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England

[4] Maastricht Univ, Dept Clin Pharm & Toxicol, Med Ctr, NL-6200 MD Maastricht, Netherlands

[5] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, NL-6200 MD Maastricht, Netherlands

[6] Univ Manchester, Farr Inst, Manchester, Lancs, England

[7] Viecuri MC Venlo, Dept Internal Med, Venlo, Netherlands

[8] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, NL-6200 MD Maastricht, Netherlands

[9] Hasselt Univ, Biomed Res Inst, Hasselt, Belgium

[10] Univ Med Ctr Utrecht, Dept Clin Pharm, Utrecht, Netherlands

[11] St Antonius Hosp, ILD Ctr Excellence, Nieuwegein, Netherlands

[12] Maastricht Univ, Dept Pharmacol & Toxicol, FHML, NL-6200 MD Maastricht, Netherlands

[13] Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands

来源：

OSTEOPOROSIS INTERNATIONAL | 2016年 / 27卷 / 04期

关键词：

Bone; Epidemiology; Fractures; Glucocorticoids; Osteoporosis; Sarcoidosis; BONE-MINERAL DENSITY; C-REACTIVE PROTEIN; CALCIUM-METABOLISM; WOMENS HEALTH; OSTEOPOROSIS; DISORDERS; ARTHRITIS; FRAGILITY; DISEASE;

D O I：

10.1007/s00198-015-3426-1

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

In this retrospective cohort study using the Clinical Practice Research Datalink (CPRD), patients with sarcoidosis have an increased risk of clinical vertebral fractures and when on recent treatment with oral glucocorticoids, also an increased risk of any fractures and osteoporotic fractures. Sarcoidosis is a chronic inflammatory disease, in which fragility fractures have been reported despite normal BMD. The aim of this study was to assess whether patients with sarcoidosis have an increased risk of clinical fractures compared to the general population. A retrospective cohort study was conducted using the CPRD. All patients with a CPRD code for sarcoidosis between January 1987 and September 2012 were included. Cox proportional hazards models were used to derive adjusted relative risks (RRs) of fractures in all sarcoidosis patients compared to matched controls, and within the sarcoidosis group according to use and dose of systemic glucocorticoids. Five thousand seven hundred twenty-two sarcoidosis patients (mean age 48.0 years, 51 % females, mean follow-up 6.7 years) were identified. Compared to 28,704 matched controls, the risk of any fracture was not different in patients with sarcoidosis. However, the risk of clinical vertebral fractures was significantly increased (adj RR 1.77; 95 % CI 1.06-2.96) and the risk of non-vertebral fractures was decreased although marginally significant (adj RR 0.87; 95 % CI 0.77-0.99). Compared to sarcoidosis patients not taking glucocorticoids, recent use of systemic glucocorticoids was associated with an increased risk of any fracture (adj RR 1.50; 95 % CI 1.20-1.89) and of an osteoporotic fracture (adj RR 1.47; 95 % CI 1.07-2.02). Patients with sarcoidosis have an increased risk of clinical vertebral fractures, and when using glucocorticoid therapy, an increased risk of any fractures and osteoporotic fractures. In contrast, the risk of non-vertebral fractures maybe decreased. Further investigation is needed to understand the underlying mechanisms of these contrasting effects on fracture risk.

引用

页码：1603 / 1610

页数：8

共 48 条

[1]

C-reactive protein and fracture risk: European Prospective Investigation into Cancer Norfolk Study [J].